Institutional readiness for novel therapeutics: A framework for multidisciplinary integration.

Area of Science:

• Pharmacology
• Medical Practice
• Health Services Research

Background:

• The development of novel therapeutics for rare diseases is rapidly advancing.
• Approved treatments include antisense oligonucleotides, enzyme replacement therapies, targeted small molecules, mRNA, and gene replacement therapies.
• Integrating these high-cost treatments into clinical practice poses significant challenges.

Purpose of the Study:

• To outline practical aspects of implementing recently approved non-gene therapy therapeutics for rare diseases in clinical settings.
• To focus on the multidisciplinary efforts, coordination, and barriers to successful integration.
• To provide strategies for navigating the complexities of these advanced treatments.

Main Methods:

• Focused review of recently approved non-gene therapy therapeutics for rare diseases.
• Analysis of implementation strategies, including multidisciplinary team coordination.
• Examination of institutional and insurance-related barriers and potential solutions.

Main Results:

• Successful implementation requires strong institutional support and comprehensive infrastructure, including specialized clinics and pharmacy services.
• Key strategies involve developing new treatment protocols, securing payor support, and coordinating with pharmaceutical companies.
• A well-coordinated, institution-wide approach is crucial for addressing clinical and logistical challenges.

Conclusions:

• Effective deployment of new rare disease therapeutics demands a holistic, institution-wide strategy.
• Emphasis on multidisciplinary collaboration and patient-centric care is essential.
• Navigating these complexities can improve outcomes and access for patients with rare diseases.